Engineering high-affinity PD-1 variants for optimized immunotherapy and...
Abstract Signaling through the immune checkpoint programmed cell death protein-1 (PD-1) enables tumor progression by dampening antitumor immune responses. Therapeutic blockade of the signaling axis...
View ArticleImmune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy...
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced the start of a...
View ArticleImmunoCellular Therapeutics Enters into Sponsored Research Agreement with...
(Source: ImmunoCellular Therapeutics Ltd) LOS ANGELES, Nov. 12, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ('ImmunoCellular') (NYSE MKT: IMUC) today announced it has entered into a...
View ArticleData from CytomX's Probody™ Pipeline to be Presented at the 2015...
(Source: CytomX Therapeutics Inc) SOUTH SAN FRANCISCO, Calif., Oct. 26, 2015 /PRNewswire/ -- CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing Probody™ therapeutics for the...
View ArticleImmunoCellular Therapeutics Enters into Sponsored Research Agreement with...
LOS ANGELES, Nov. 12, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced it has entered into a sponsored research agreement with Dr. Cassian Yee...
View ArticleData from CytomX's Probody™ Pipeline to be Presented at the 2015...
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2015 /PRNewswire/ -- CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing Probody™ therapeutics for the treatment of cancer, today announced...
View ArticleSELLAS Life Sciences Appoints Acclaimed Cancer Researchers Drs. Larry W. Kwak...
ZUG, Switzerland and NEW YORK, Nov. 11, 2015 /PRNewswire/ -- SELLAS Life Sciences Group (SELLAS), a development-stage biopharmaceutical company focused on innovative products to treat cancers and...
View ArticleImmune Design Presents Preclinical Data on G100 and ZVex(TM) in Combination...
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 3, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced new preclinical data...
View ArticleCytomX Highlights Data from Multiple Probody Pipeline Programs at Investor...
BOSTON, Nov. 8, 2015 /PRNewswire/ -- CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, highlighted data...
View ArticleXencor to Host Third Quarter 2015 Financial Results Webcast and Conference...
MONROVIA, Calif., Oct. 27, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Presents Data on XmAb5871 Program at American College of Rheumatology...
MONROVIA, Calif., Nov. 9, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleDelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in...
VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 6, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the...
View ArticleDaratumumab Approved for Advanced Multiple Myeloma (ASHP - American Society...
(Source: ASHP - American Society of Health-System Pharmacists) BETHESDA, MD 17 Nov 2015- FDA and Janssen on November 16 announced the licensing of daratumumab for i.v. infusion for the treatment of...
View ArticleApexigen Presents Positive Data for APX005M in Podium Presentation at Immune...
SAN CARLOS, Calif., Nov. 17, 2015 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of...
View ArticleDARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38...
(Source: Johnson & Johnson) First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an...
View ArticleGenmab Announces U.S. FDA Approval of DARZALEX(TM) (daratumumab) for Multiple...
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA for heavily pre-treated or double refractory multiple myeloma First monoclonal antibody approved for multiple myeloma Financial guidance...
View ArticleZIOPHARM Announces Data Highlighting Ad-RTS-hIL-12 Activity in Glioma at SNO
BOSTON, Nov. 19, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced that the Company is presenting...
View ArticleFive Prime Therapeutics Begins Dose Expansion in Gastric Cancer Patients With...
(Source: Five Prime Therapeutics Inc) November 19, 2015 SOUTH SAN FRANCISCO, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology...
View ArticleJanssen's New Drug Submission for Daratumumab for Treatment of Multiple...
(Source: Johnson & Johnson) 7a0aabb9-0888-4668-8358-93cee0e0424d.pdf November 18, 2015 Janssen's New Drug Submission for Daratumumab for Treatment of Multiple Myeloma Accepted for Review by Health...
View ArticleGenmab Achieves USD 45 Million Milestone in DARZALEX(TM) (daratumumab)...
Company Announcement Genmab to receive USD 45 million milestone payment from Janssen Milestone triggered by first commercial sale of DARZALEX in the United States COPENHAGEN, Denmark, Nov. 19, 2015...
View Article